Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy

Condition:   Nasopharyngeal Carcinoma Intervention:   Drug: Anlotinib Sponsor:   Sun Yat-sen University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials